Home Business Eli Lilly to buy Loxo Oncology for about $8 billion in cancer bet – CNBC

Eli Lilly to buy Loxo Oncology for about $8 billion in cancer bet – CNBC

11 min read

Eli Lilly said on Monday it would buy Loxo Oncology for about $8 billion in cash, buying into a portfolio of targeted medicines to treat cancers.

The offer of $235 per share in cash represents a premium of about 68 percent to Loxo’s Friday close. Loxo’s shares surged 32.8 percent to $185.70 in light trading before the bell, while those of Lilly dropped 2.7 percent to $111.60.

Last year, U.S. regulators approved Loxo’s first commercial medicine, Vitrakvi, which was shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation. The drug is sold in partnership with Bayer.

Loxo Oncology is developing a pipeline of targeted medicines focused on such cancers that can be detected by genomic testing.

Deutsche Bank is Lilly’s financial adviser and Weil, Gotshal & Manges is its legal adviser. Goldman Sachs is the financial adviser, while Fenwick & West is legal adviser to Loxo.

The Lilly acquisition comes a week after Bristol-Myers Squibb announced plans to buy Celgene in a blockbuster $74 billion deal.

CNBC contributed to this report.

Let’s block ads! (Why?)

Source link


Check Also

Harley pulls plug on LiveWire production shortly after EV debut – TechCrunch

Loading...   Harley-Davidson has halted production and delivery of its first electric…